(Q37765473)

22 August 2017

1 reference

title

Fingolimod is a potential novel therapy for multiple sclerosis (English)

1 reference

22 August 2017

0 references

4

Hans-Peter Hartung

1 reference

22 August 2017

3

Bernd Kieseier

1 reference

22 August 2017

Orhan Aktas

1

1 reference

PubMed ID

20551946

22 August 2017

Patrick Küry

series ordinal

2

1 reference

PubMed ID

20551946

22 August 2017

language of work or name

English

0 references

publication date

15 June 2010

1 reference

22 August 2017

Nature Reviews Neurology

1 reference

22 August 2017

6

1 reference

22 August 2017

7

1 reference

22 August 2017

373-382

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2010.76

22 August 2017

0 references

cites work

Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite

2 references

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

31 March 2020

12 December 2020

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Finding a way out: lymphocyte egress from lymphoid organs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Central nervous system-directed effects of FTY720 (fingolimod).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

"Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Lysophospholipid receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Sphingosine-1-phosphate: an enigmatic signalling lipid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Emerging medicinal roles for lysophospholipid signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

The alliance of sphingosine-1-phosphate and its receptors in immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Follicular shuttling of marginal zone B cells facilitates antigen transport

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

S1P3 confers differential S1P-induced migration by autoreactive and non-autoreactive immature B cells and is required for normal B-cell development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Autoimmune T cell responses in the central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Disturbed regulatory T cell homeostasis in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Role of the innate immune system in the pathogenesis of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Multiple sclerosis--the plaque and its pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Active induction of experimental allergic encephalomyelitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Neuronal damage in brain inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

FTY720 modulates human oligodendrocyte progenitor process extension and survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Molecular dissection of reactive astrogliosis and glial scar formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Sirt1 contributes critically to the redox-dependent fate of neural progenitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Antiproliferative properties of sphingosine-1-phosphate in human hepatic myofibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Sphingosine-1-phosphate induces apoptosis of cultured hippocampal neurons that requires protein phosphatases and activator protein-1 complexes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Origin of oligodendrocytes in the subventricular zone of the adult brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Essential role for sphingosine kinases in neural and vascular development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Oral fingolimod (FTY720) for relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Oral therapies for multiple sclerosis: are we there yet?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Development of oral cladribine for the treatment of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Lysophospholipid receptors: signaling and biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Lysophospholipid receptors are differentially expressed in rat terminal Schwann cells, as revealed by a single cell rt-PCR and in situ hybridization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.76

FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homin

31 March 2020

1 reference

12 December 2020

First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients

1 reference

12 December 2020

Sphingosine-1-phosphate rapidly induces Rho-dependent neurite retraction: action through a specific cell surface receptor

1 reference

12 December 2020

EDG receptors as a therapeutic target in the nervous system

1 reference

12 December 2020

Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells

1 reference

12 December 2020

FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.

1 reference

12 December 2020

Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2010.76

1 reference

22 August 2017

1 reference

PubMed ID

20551946